Uncategorized-EN
SPAGN Annual Conference 2025
We are thrilled to announce that the SPAGN Annual Conference 2025 will be held in Washington D.C., USA, from April 11-13, 2025. This will be our first conference in the United States, marking a significant milestone for our global community. This highly anticipated event will bring together patient advocates from around the world to discuss…
Read MoreNot just any cancer information day…. from the diary of a patient advocate
More than five years after therapy, our Editor-in-Chief Gabi Ott went back to the hospital where she was treated. But this time, it was not as a patient but as a patient advocate. Together with her colleagues, she attended to people looking for information on sarcoma. Being in the building also brought back memories of her darkest days – and the many people who helped her during this journey. A tribute to the nurses and doctors, and a patient organization.
Read MorePatient Advocacy @CTOS 2024
We are delighted to announce that patient advocacy will once again have a valued presence at the Connective Tissue Oncology Society (CTOS) Annual Meeting. This year, we are pleased to host the Patient Advocacy Lounge at CTOS 2024 in San Diego: Patient Advocacy LoungeRoom Balboa ABC, Second Level, Manchester Grand Hyatt San DiegoOpen from Thursday, November…
Read MoreYour Poster @CTOS 2025
đź“Ł Share Your Advocacy Work with the Global Sarcoma Community at CTOS 2025 Make your voice heard and your impact visible — Create and submit a poster to be featured on the Patient Advocacy Poster Wall! Sarcoma patient advocacy organizations are cordially invited to participate in SPAGN’s poster presentation session that will be held at…
Read MoreACF’s European Manifesto: Addressing Critical Gaps in Research and Treatment of Rare Cancers🎗️
The Anticancer Fund (ACF) has launched its European Manifesto 2024, presenting a forward-looking strategy to position Europe as a global leader in cancer treatment innovation. With cancer rates set to rise dramatically—35 million new cases projected by 2050—there’s no time to waste. đź•’ SPAGN fully supports the goals set out by the ACF in its…
Read MoreBridging the Gap in Sarcoma Care: A Vision for South Africa
Sarcoma patients in South Africa struggle to find the expertise required for correct diagnosis and appropriate treatment. Lauren Pretorius, Chief Executive Office of Campaigning for Cancer, provides her vision on how sarcoma care in South Africa can be transformed.
Read MoreKey Findings from Phase II of the SPAGN Priority Setting Partnership published đź“ť
The Sarcoma Patient Advocacy Global Network (SPAGN) has published the results of the second phase of its Priority Setting Partnership (PSP), focusing on identifying research and patient advocacy priorities in sarcoma care, in “BMC Cancer”. This initiative is groundbreaking as it actively involves patients and carers in shaping the research agenda, ensuring their voices are…
Read MoreSave the Date: SPAGN Annual Conference 2025 in Washington D.C.!đź“…
We are thrilled to announce that the SPAGN Annual Conference 2025 will be held in Washington D.C., USA, from April 11-13, 2025. This will be our first conference in the United States, marking a significant milestone for our global community. This highly anticipated event will bring together patient advocates from around the world to discuss…
Read MoreCabozantinib in children, adolescents and young adults with osteosarcoma (CabOSTar)
Trial name Cabozantinib in osteosarcoma Agents Cabozantinib Phase II Status Recruiting Sponsor Ipsen This is a randomized, open-label Phase II study to assess the efficacy and safety of maintenance therapy with cabozantinib plus best supportive care (BSC) vs. BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma. Further information can…
Read MoreIvosidenib in Conventional Chondrosarcoma (CHONQUER)
Trial name: Ivosidenib in conventional chondrosarcoma Agents: Ivosidenib, placebo Phase III Status Recruiting Sponsor Servier Bio-Innovation LLC This study is a randomized, double-blinded, placebo-controlled phase 3 study of Ivosidenib in locally advanced or metastatic conventional chondrosarcoma patients. Further information can be found on clinicaltrials.gov. WHO is the trial for? Adult patients with…
Read More